Common filaggrin gene mutations and risk of cervical cancer

Figures & data

Figure 1. Genotypic-specific and general survival after cervical cancer, Denmark. Survival since diagnosis of cervical cancer is shown for cases in the study sampled for genotyping blood until 2011 [red (lower) curve, FLG mutation carriers; blue curve, wildtype carriers], and for all cases in Denmark (green curve). The latter was the expected survival estimated based on all cases of cervical cancer in Denmark using direct-adjusted survival with age at diagnosis as covariate. The lower table shows number of studied cases at risk of death at selected time points during follow-up.

Table I. Characteristics of 586 cases of cervical cancer diagnosed 1967–2011 and 8050 controls from the capital region in Denmark.

	Cases n	(%)	Controls n	(%)
Year of blood sampling
1993–2008	0	(0)	8075	(100)
2009–2013	586	(100)	0	(0)
Age at blood sampling (years)
10–19	0	(0)	13	(0)
20–29	37	(6)	1103	(14)
30–39	103	(18)	1665	(21)
40–49	114	(19)	2103	(26)
50–59	91	(16)	1944	(24)
60–69	127	(22)	961	(12)
70–79	67	(11)	286	(4)
80–89	41	(7)	0	(0)
90–99	7	(1)	0	(0)

Table II. Odds ratio (OR) of cervical cancer according to filaggrin genotype (R501X /2282del4, wildtype) when comparing cases and controls from the capital region in Denmark.

Genotype	Cases (%)	Controls (%)	Crude OR (95% CI)	Adjusted for blood sampling age OR (95% CI)
Wildtype	549 (93.7)	7430 (92.3)	1 (ref.)	1 (ref.)
1 or both mutations	37 (6.3)	620 (7.7)	0.81 (0.57–1.14)	0.74 (0.51–1.06)
Heterozygous	35 (6.0)	597 (7.4)	0.79 (0.56–1.13)	0.74 (0.51–1.07)
Homozygous*	2 (0.3)	23 (0.3)	1.18 (0.28–5.00)	0.81 (0.17–3.88)

CI, confidence intervals.

*Includes compound heterozygous (0 cases and 5 controls).

Table III. Hazard ratio (HR) of death after cervical cancer according to filaggrin genotype (R501X /2282del4, wildtype) among cases sampled for genotyping blood until 2011,* capital region, Denmark.

Genotype	Cervical cancer cases n	Follow-up years	Dead n	Crude HR (95% CI)	Adjusted for age** HR (95% CI)	Adjusted for age** and stratification by stage HR (95% CI)
Death from cervical cancer
Wildtype	391	494	42	1 (ref.)	1 (ref.)	1 (ref.)
Mutation	37	10	5	4.09 (1.58–10.62)	4.55 (1.70–12.2)	2.53 (0.84–7.59)
Death from other cause
Wildtype	391	494	55	1 (ref.)	1 (ref.)	1 (ref.)
Mutation	37	10	2	0.95 (0.19–4.65)	1.33 (0.27–6.57)	1.03 (0.19–5.75)

CI, confidence intervals.

*158 of 586 cases were sampled 2012–2013 and were excluded because information on cause-specific mortality was not available; **Age at diagnosis.